A Randomised Controlled Trial on the Clinical Efficacy of Oral Trehalose in Patients With Spinocerebellar Ataxia 3: Clinical & FMRI Correlation
Status: Unknown
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study evaluates the effectiveness of oral trehalose in alleviating the neuropathological and motor behaviour deficits among patients with SCA3. A total of 40 participants with SCA3 will be recruited, with 20 participants to be administered with trehalose while another 20 participants to be administered with a maltose placebo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:
• Age between 18 and 85 years old.
• Genetically confirmed SCA 3 diagnosis.
• Presence of progressive cerebellar syndrome (i.e. symptomatic) and genetic confirmation of SCA 3 in one of the immediate family members with similar clinical syndrome.
• Able to read, speak, and understand English or Malay.
Locations
Other Locations
Malaysia
UKM Medical Centre
RECRUITING
Cheras
Contact Information
Primary
Kah Hui Yap, Master
kahhui0411@gmail.com
+60165536721
Backup
Norlinah Mohamed Ibrahim, MRCP
norlinah@ppukm.ukm.edu.my
+60122145306
Time Frame
Start Date: 2020-02-24
Completion Date: 2023-06-30
Participants
Target number of participants: 20
Treatments
Experimental: Trehalose
Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
Placebo_comparator: Maltose placebo
Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
Related Therapeutic Areas
Sponsors
Collaborators: Radboud University Medical Center
Leads: National University of Malaysia